Skip to main content

Table 1 Participant characteristics for 1466 lung cancer survivors by Baecke physical activity data

From: Impact of self-reported physical activity and health promotion behaviors on lung cancer survivorship

Participant characteristic Non-physically active (N = 331) Physically active (N = 1135) Total (N = 1466)
Age at diagnosis    
N 331 1135 1466
 Mean (SD) 68.7 (9.73) 64.9 (10.82) 65.7 (10.7)
 Range (35.0–91.0) (18.0–93.0) (18–93)
Gender    
 Female 158 (47.7 %) 568 (50 %) 726 (49.5 %)
 Male 173 (52.3 %) 567 (50 %) 740 (50.5 %)
Race    
 Caucasian 311 (94 %) 1059 (93.3 %) 1370 (93.5 %)
 Hispanic 4 (1.2 %) 8 (0.7 %) 12 (0.8 %)
 Alaskan/Indian 15 (4.5 %) 54 (4.8 %) 69 (4.7 %)
 Black 1 (0.3 %) 3 (0.3 %) 4 (0.3 %)
 Asian/Pacific Islander 0 (0.0 %) 6 (0.5 %) 6 (0.4 %)
 Unknown 0 (0.0 %) 5 (0.4 %) 5 (0.3 %)
Years of schooling completed    
 N 67 307 374
 Mean (SD) 13.0 (2.35) 13.6 (2.41) 13.5 (2.4)
 Range (6.0–17.0) (5.0–18.0) (5.0–18.0)
Marital status    
 Missing 62 185 247
 Single 9 (3.3 %) 47 (4.9 %) 56 (4.6 %)
 Married 194 (72.1 %) 751 (79.1 %) 945 (77.5 %)
 Divorced 27 (10 %) 75 (7.9 %) 102 (8.4 %)
 Widowed 39 (14.5 %) 75 (7.9 %) 114 (9.4 %)
 Life partner 0 (0.0 %) 2 (0.2 %) 2 (0.2 %)
Vital status (as of 2/2010)    
 Alive 167 (50.5 %) 787 (69.3 %) 954 (65.1 %)
 Dead 164 (49.5 %) 348 (30.7 %) 512 (34.9 %)
Time to last FU (as of 2/2010) in years    
 N 331 1135 1466
 Mean (SD) 2.7 (2.15) 3.3 (2.43) 3.1 (2.38)
 Range (0.1–8.6) (0.0–9.0) 2.2
Cigarette smoking status    
 Never 36 (10.9 %) 218 (19.2 %) 254 (17.3 %)
 Former smoker 165 (49.8 %) 615 (54.2 %) 780 (53.2 %)
 Current smoker 129 (39 %) 294 (25.9 %) 423 (28.9 %)
 Some smoking history 1 (0.3 %) 8 (0.7 %) 9 (0.6 %)
Pack-Years    
 N 292 910 1202
 Mean (SD) 53.2 (34.44) 45.4 (28.29) 47.3 (30.07)
 Range (0.5–208.0) (0.0–180.0) (0.0–208.0)
Condensed grade    
 Missing 1 6 7
 1 = Well differentiated 58 (17.6 %) 328 (29.1 %) 386 (26.5 %)
 2 = Moderately differentiated 104 (31.5 %) 414 (36.7 %) 518 (35.5 %)
 3 = Poorly differentiated 142 (43 %) 321 (28.4 %) 463 (31.7 %)
 4 = Non-gradeable 26 (7.9 %) 66 (5.8 %) 92 (6.3 %)
Stage    
 Missing 6 5 11
 Limited 27 (8.3 %) 36 (3.2 %) 63 (4.3 %)
 Extensive 22 (6.8 %) 30 (2.7 %) 52 (3.6 %)
 Stage IA 49 (15.1 %) 320 (28.3 %) 369 (25.4 %)
 Stage IB 48 (14.8 %) 186 (16.5 %) 234 (16.1 %)
 Stage IIA 6 (1.8 %) 24 (2.1 %) 30 (2.1 %)
 Stage IIB 17 (5.2 %) 68 (6 %) 85 (5.8 %)
 Stage IIIA 42 (12.9 %) 124 (11 %) 166 (11.4 %)
 Stage IIIB 45 (13.8 %) 116 (10.3 %) 161 (11.1 %)
 Stage IV 69 (21.2 %) 226 (20 %) 295 (20.3 %)
T (tumor) of TNM staging    
 Missing 69 176 245
 No primary tumor 6(2.3 %) 10(1.0 %) 16(1.3 %)
 Tumor < = 3 cm 83 (31.7 %) 420 (43.8 %) 503 (41.2 %)
 Tumor > 3 cm 92 (35.1 %) 309 (32.2 %) 401 (32.8 %)
 Invades chest wall 14 (5.3 %) 54 (5.6 %) 68 (5.6 %)
 Invades mediastinum 56 (21.4 %) 137 (14.3 %) 193 (15.8 %)
 Cannot be assessed 11 (4.2 %) 29 (3 %) 40 (3.3 %)
N (nodes) of TNM staging    
 Missing 51 123 174
 No nodal mets 122 (43.6 %) 611 (60.4 %) 733 (56.7 %)
 In Peribr/Hilar 30 (10.7 %) 98 (9.7 %) 128 (9.9 %)
 In Medias/Subcarinal 97 (34.6 %) 210 (20.8 %) 307 (23.8 %)
 Mets in contralaterl 22 (7.9 %) 76 (7.5 %) 98 (7.6 %)
 Nodes Unassessable 9 (3.2 %) 17 (1.7 %) 26 (2 %)
Surgery    
 Missing 12 27 39
 No 179 (56.1 %) 381 (34.4 %) 560 (39.2 %)
 Yes 140 (43.9 %) 727 (65.6 %) 867 (60.8 %)
Surgery within 6 months    
 Missing 12 27 39
 No 189 (59.2 %) 435 (39.3 %) 624 (43.7 %)
 Yes 130 (40.8 %) 673 (60.7 %) 803 (56.3 %)
Chemotherapy    
 Missing 12 27 39
 No 120 (37.6 %) 542 (48.9 %) 662 (46.4 %)
 Yes 199 (62.4 %) 566 (51.1 %) 765 (53.6 %)
Chemotherapy within 6 months    
 Missing 12 27 39
 No 166 (52 %) 686 (61.9 %) 852 (59.7 %)
 Yes 153 (48 %) 422 (38.1 %) 575 (40.3 %)
Radiation    
 Missing 12 27 39
 No 193 (60.5 %) 769 (69.4 %) 962 (67.4 %)
 Yes 126 (39.5 %) 339 (30.6 %) 465 (32.6 %)
Radiation within 6 months    
 Missing 12 27 39
 No 230 (72.1 %) 875 (79 %) 1105 (77.4 %)
 Yes 89 (27.9 %) 233 (21 %) 322 (22.6 %)